Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The FLARE score and circulating neutrophils in patients with cancer and COVID-19 disease

  • Seguí, Elia
  • Casadevall Aguilar, David
  • Mezquita, Laura
Purpose: Inflammation and neutrophils play a central role in both COVID-19 disease and cancer. We aimed to assess the impact of pre-existing tumor-related inflammation on COVID-19 outcomes in patients with cancer and to elucidate the role of circulating neutrophil subpopulations. Methods: We conducted a multicenter retrospective analysis of 524 patients with cancer and SARS-CoV-2 infection, assessing the relationship between clinical outcomes and circulating inflammatory biomarkers collected before and during COVID-19 infection. Additionally, a single-center prospective cohort study provided data for an exploratory analysis, assessing the immunophenotype of circulating neutrophils and inflammatory cytokines. The primary endpoints were 30-day mortality and the severity of COVID-19 disease. Results: Prior to COVID-19, 25% of patients with cancer exhibited elevated dNLR, which increased to 55% at the time of COVID-19 diagnosis. We developed the FLARE score, incorporating both tumor- and infection-induced inflammation, which categorized patients into four prognostic groups. The poor prognostic group had a 30-day mortality rate of 68%, significantly higher than the 23% in the favorable group (p < 0.0001). This score proved to be an independent predictor of early mortality. This prospective analysis revealed a shift towards immature forms of neutrophils and higher IL-6 levels in patients with cancer and severe COVID-19 infection. Conclusions: A pre-existing tumor-induced pro-inflammatory state significantly impacts COVID-19 outcomes in patients with cancer. The FLARE score, derived from circulating inflammatory markers, emerges as an easy-to-use, globally accessible, effective tool for clinicians to identify patients with cancer at heightened risk of severe COVID-19 complications and early mortality who might benefit most from immediate and intensive treatment strategies. Furthermore, our findings underscore the significance of immature neutrophils in the progression of COVID-19 in patients with cancer, advocating for further investigation into how these cells contribute to both cancer and COVID-19 disease., E.S. was supported by the Contracte Clínic Recerca “Emili Letang i Josep Font” 2022 and I Predoctoral Grant in Precision Oncology, 2022 (Cátedra UB IOP). L.M. received funding from the Beca SEOM retorno 2019; ESMO fellowship 2019–2021; Contrato Juan Rodes 2020 (ISCIII, Ministry of Health; JR20/00019); Ayuda Juan Rodés SEOM 2020; Ayuda de la Acción Estratégica en Salud—ISCIII FIS 2021 (PI21/01653); Beca SEOM para Proyectos de Investigación en Immunoncología 2021; Beca SEOM-ASTRAZENECA para Proyectos de Investigación para Grupo Emergente 2022; RADONORM, funded by the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 900009; Grupo Español de Tumores Huérfanos e infrecuentes (GETHI), Convocatoria Inés de Pablo Llorens 2023; and Becas Gilead a la Investigación Biomédica 2023. A.P. received funding from the Fundación CRIS contra el cáncer PR_EX_2021–14, Agència de Gestó d’Ajuts Universitaris i de Recerca 2021 SGR 01156, Fundación Fero BECA ONCOXXI21, Instituto de Salud Carlos III PI22/01017, Asociación Cáncer de Mama Metastásico IV Premios M. Chiara Giorgetti, Breast Cancer Research Foundation BCRF-23–198, and RESCUER, funded by the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 847912. Any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of funding entities. The preliminary results of this study were presented at ESMO Congress 2020 [38] and ASCO 2022 [39] as poster communications. During the preparation of this work, the author(s) used ChatGPT4 in the writing process. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Clinical, pathological and PAM50 gene expression features of HER2-low breast cancer

  • Prat Aparicio, Aleix
  • Schettini, Francesco
  • Chic Ruché, Núria
  • Brasó-Maristany, Fara
  • Paré, Laia
  • Pascual, Tomás
  • Conte, Benedetta
  • Martínez-Sáez, Olga
  • Adamo, Barbara
  • Vidal Losada, Maria
  • Fernández Martínez, Aranzazu
  • González Farré, Blanca
  • Sanfeliu Torres, Esther
  • Cejalvo Andújar, Juan Miguel
  • Perrone, Giuseppe
  • Sabarese, Giovanna
  • Zalfa, Francesca
  • Villagrasa, Patricia
  • Gavilá, Joaquín
  • Barrios, Carlos H.
  • Lluch, Ana
  • Martín, Miguel
  • Placido, Sabino De
  • Barnadas, Esther
  • Locci, Mariavittoria
  • Peg, Vicente
  • Fasan, Roberta
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

ERBB2mRNA expression and response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-positive breast cancer

  • Griguolo, Gaia
  • Brasó-Maristany, Fara
  • González Farré, Blanca
  • Pascual, Tomás
  • Chic Ruché, Núria
  • Saurí, Tamara
  • Kates, Ronald
  • Gluz, Oleg
  • Martínez, Débora
  • Paré, Laia
  • Tsvetkova, Vassilena
  • Pesantez, David
  • Vidal Losada, Maria
  • Adamo, Barbara
  • Muñoz Mateu, Montserrat
  • Galván, Patricia
  • Barberá, Laura
  • Cuatrecasas Freixas, Miriam
  • Christgen, Mathias
  • Kreipe, Hans
  • Monge Escartín, Inés
  • Villagrasa, Patricia
  • Soy Muner, Dolors
  • Giarratano, Tommaso
  • Dieci, Maria Vittoria
  • Conte, Pierfranco
  • Harbeck, Nadia
  • Guarneri, Valentina
  • Prat Aparicio, Aleix
Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA.We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed para n-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally,
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

  • Martínez-Sáez, Olga
  • Chic Ruché, Núria
  • Pascual, Tomás
  • Adamo, Barbara
  • Vidal Losada, Maria
  • Gonzalez-Farre, Xavier
  • Sanfeliu Torres, Esther
  • Schettini, Francesco
  • Conte, Benedetta
  • Brasó-Maristany, Fara
  • Rodriguez, Adela
  • Martínez, Debora
  • Galván, Patricia
  • Rodríguez, Ana Belén
  • Martínez, Antonio
  • Muñoz Mateu, Montserrat
  • Prat Aparicio, Aleix
Purpose: The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects most PIK3CA mutations in BC. This information is critical as patients and clinicians are using this and other genomic assays to indicate alpelisib. Methods: Data from 6338 patients with BC was explored across 10 publicly available studies. The primary objective was to evaluate the proportion and distribution of PIK3CA mutations in BC. Secondary objectives were (1) to evaluate in silico the spectrum of PIK3CA mutations in BC that would be captured by the therascreen panel; (2) to evaluate the proportion and distribution of PIK3CA mutations in hormone receptor-positive/HER2-negative (HR+/HER2-), HER2+, and triple-negative BC (TNBC); and (3) to explore the identification of PIK3CA mutations in a cohort of 48 HR+/HER2- advanced BC patients by the Guardant B360 circulating tumor DNA (ctDNA) assay. Results: Patients with PIK3CAmut tumors represented 35.7% (2261/6338). Five PIK3CA mutations comprised 73% of all PIK3CA mutations: H1047R (35%), E545K (17%), E542K (11%), N345K (6%), and H1047L (4%). Therascreen gene list would capture 72% of all PIK3CA mutations and 80% of patients with a known PIK3CAmut BC. Among patients with double PIK3CAmut tumors (12% of all PIK3CAmut), the therascreen panel would capture 78% as harboring 1 single PIK3CA mutation, 17% as PIK3CAmut undetected, and 5% as PIK3CA double-mut. PIK3CA mutation rates were lower in TNBC (16%) compared to HR+/HER2 (42%) and HER2+ (31%) BC; however, the distribution of the 4 main PIK3CA mutations across subtypes was similar. Finally, 28% of PIK3CA mutations identified in ctDNA in 48 patients with advanced HR+/HER2- BC were not part of the therascreen panel. Conclusion: PIK3CA mutations in BC are heterogenous and ~ 20% of patients with a known PIK3CA mutation, and 95% with a known double PIK3CAmut tumor, would not be captured by the therascreen panel. Finally, the clinical utility of PIK3CA mutations not present in the therascreen companion diagnostic assay or identified by other sequencing-based assays needs further investigation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The harmonized activities of HER2-HER3 heterodimer and deacetylated FOXA1 evade hormone response by regulating FOXA1 chromatin binding

  • Wang, Shixiong
  • Santacana-Font, Gemma
  • Kedra, Darek
  • Gilfillan, Siv
  • Tena-Chaves, David
  • Bergholtz, Helga
  • Engebraaten, Olav
  • Lingjaerde, Ole Christian
  • Gutiérrez-Fernández, Javier
  • Norum, Jens Henrik
  • Sørlie, Therese
  • López-Avilés, Sandra
  • Hurtado, Antoni
FOXA1 is a key transcription factor that mediates the effects of estrogen receptor (ER) and HER2 signaling in breast cancer. However, the mechanisms underlying FOXA1 regulation by HER2 and ER remain poorly understood. Here, we investigated FOXA1 regulation in cells with varying HER2 levels and its impact on endocrine therapy response. Chromatin interaction analyses revealed that high HER2 levels enhance FOXA1 binding to chromatin regions while reducing ER occupancy. Mechanistically, FOXA1 is acetylated by the histone acetyltransferase EP300 at the WD1 domain in ER-positive cells, attenuating its DNA binding at HER2-induced chromatin regions. Conversely, FOXA1 deacetylation-triggered by HER2/HER3 activation-increases its binding to ER-independent regions and promotes insensitivity to hormone therapy. In a luminal breast cancer patient-derived xenograft model, HER2/HER3 signaling increased FOXA1 chromatin binding and reduced sensitivity to ER-targeted treatment. We identify HDAC2 as a key deacetylase modulating FOXA1 acetylation and partially mediating the effects of HER2/HER3 signaling. Altogether, our findings highlight the significance of FOXA1 acetylation, regulated by the HER2/HER3-HDAC2-FOXA1 axis, in controlling FOXA1 chromatin binding and shaping breast cancer progression and therapy response. These insights may inform future therapeutic strategies., This work was supported the European Union’s Horizon 2020 Research and Innovation Program [No. 847912] and from Programa de generación de conocimiento del Ministerio Ciencia y Tecnologia del Gobierno de España [PGC2018-099175-B-I00]. Funding to pay the Open Access publication charges for this article was provided by RESCUER (H2020 grant), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)

  • Pascual, Tomás
  • Vidal, Maria
  • Cejalvo, Juan M
  • Vega, Estela
  • Sanfeliu, Esther
  • Villacampa, Guillermo
  • Ganau, Sergi
  • Parreño, Ana María Julve
  • Zamora, Esther
  • Miranda, Ignacio
  • Delgado, Ana
  • Bermejo, Begoña
  • Seguí, Elia
  • Brasó-Maristanty, Fara
  • Cruz-Merino, Luis de la
  • Juan, Manel
  • Galván, Patricia
  • Gonzàlez-Farré, Xavier
  • Chillara, Samyukta
  • Villagrasa, Patricia
  • Pfefferle, Adam D
  • O'Connell, Constandina E
  • Ferrero-Cafiero, Juan M
  • Oliveira, M.
  • Perou, Charles M
  • Prat, Aleix
[Data availability] The full study protocol and Statistical Analysis Plan (SAP) are provided in the Supplementary Information under the section “Supplementary Note.” RNA sequencing raw data (in the format of FASTQ files) has been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS50000001499. Further information about EGA can be found at https://ega-archive.org/datasets/EGAD50000002165. IGESs and the genes within each signature are listed in Supplementary Data 1 and 2. Source data are provided with this paper. Data are available under restricted access because participants of this study did not provide consent for public deposition of sequencing data. Deidentified patient data underlying the findings of this study are available from the corresponding author upon reasonable request. Access can be obtained for academic use only, under a data transfer agreement and upon Ethics Committee approval. The estimated timescale for this process is approximately 6 months, and the data will be available for 3 years after completion of the SOLTI-1503 PROMETEO study. Requests for access should be addressed to the corresponding author, Aleix Prat (alprat@clinic.cat). Source data are provided with this paper., This single-arm, phase II, preoperative window-of-opportunity trial (ClinicalTrials.gov Identifier: NCT03802604) investigated the efficacy and safety of talimogene laherparepvec (T-VEC), an oncolytic virus, with atezolizumab, an anti–PD-L1 antibody, in patients with breast cancer and radiologically and pathologically confirmed residual disease prior to surgery. Eligible patients had triple-negative breast cancer (TNBC) or hormone receptor-positive (HR+)/HER2-negative disease with a high proliferation index (Ki67 ≥ 20%) prior to neoadjuvant chemotherapy. Treatment consisted of one intratumoral injection of T-VEC (106 plaque-forming units [PFU]/mL), followed by four biweekly T-VEC doses (108 PFU/mL) plus atezolizumab (840 mg, intravenously). Among the 28 patients enrolled, 20 patients (71.4%) had HR+/HER2-negative and 8 patients (28.6%) had TNBC. At surgery, 7 patients (26.9%) achieved Residual Cancer Burden (RCB)−0/I (primary endpoint), 12 (46.2%) RCB-II and 7 (26.9%) RCB-III. Safety profile was favorable, with mostly low-grade adverse events and no serious events (secondary endpoint). Therapy induced immune modulation, including increased tumor-infiltrating lymphocytes, elevated PD-L1 expression, and enhanced immune-related gene signatures (exploratory endpoints). The trial met its pre-specified efficacy and safety endpoints. These findings support the feasibility of T-VEC plus atezolizumab as a preoperative immunotherapy approach for managing HER2-negative residual disease post-neoadjuvant chemotherapy and warrant further exploration in larger trials., This study was sponsored by SOLTI Cancer Research Group and supported by Amgen, Inc (no grant number) and ROCHE Farma, Inc (no grant number). SOLTI Cancer Research Group, as the academic sponsor, was involved in the study design, data collection, data analysis, data interpretation, and writing of the manuscript., Total RNA sequencing library preparation and sequencing was performed by the LCCC TGL (RRID: SCR_025231), which is supported by the Lineberger University Cancer Research Fund., Total RNAseq project management was performed by the LCCC Office of Genomics Research, which is supported in part by the Lineberger University Cancer Research Fund, by the NIH NCI 5UG1CA233333 grant, and The UNC Center for Environmental Health and Susceptibility (UNC-CEHS) P30ES010126 grant. F.B-M. received funding from Fundación científica AECC Ayudas Investigador AECC 2021 (INVES21943BRAS) and Fundación Contigo (HIMALAIA). C.M.P. was supported by funds from the NCI Breast SPORE program (P50-CA058223), the Breast Cancer Research Foundation (BCRF-23-127), and by the UNC Lineberger Triple Negative Breast Cancer Center. A.P. received funding from Instituto de Salud Carlos III and co-funded by the European Union PI22/01017, Breast Cancer Research Foundation BCRF-22-198, BCRF-23-198 and BCRF-24-198, Beca Marta Santamaría, Fundación CRIS contra el ancer PR_EX_2021-14, Agència de Gestó d’Ajuts Universitaris I de Recerca 2021 SGR 01156, Fundación Fero BECA ONCOXXI21, Asociación Cáncer de Mama Metastásico IV Premios M. Chiara Giorgetti, and RESCUER, funded by European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 847912 and Fundación Científica Asociación Española Contra el Cáncer which is the entity responsible for the financial support of the Excellence Program, EPAEC246711CLIN., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The FLARE score and circulating neutrophils in patients with cancer and COVID-19 disease

  • Seguí, Elia
  • Casadevall Aguilar, David
  • Mezquita, Laura
Purpose: Inflammation and neutrophils play a central role in both COVID-19 disease and cancer. We aimed to assess the impact of pre-existing tumor-related inflammation on COVID-19 outcomes in patients with cancer and to elucidate the role of circulating neutrophil subpopulations. Methods: We conducted a multicenter retrospective analysis of 524 patients with cancer and SARS-CoV-2 infection, assessing the relationship between clinical outcomes and circulating inflammatory biomarkers collected before and during COVID-19 infection. Additionally, a single-center prospective cohort study provided data for an exploratory analysis, assessing the immunophenotype of circulating neutrophils and inflammatory cytokines. The primary endpoints were 30-day mortality and the severity of COVID-19 disease. Results: Prior to COVID-19, 25% of patients with cancer exhibited elevated dNLR, which increased to 55% at the time of COVID-19 diagnosis. We developed the FLARE score, incorporating both tumor- and infection-induced inflammation, which categorized patients into four prognostic groups. The poor prognostic group had a 30-day mortality rate of 68%, significantly higher than the 23% in the favorable group (p < 0.0001). This score proved to be an independent predictor of early mortality. This prospective analysis revealed a shift towards immature forms of neutrophils and higher IL-6 levels in patients with cancer and severe COVID-19 infection. Conclusions: A pre-existing tumor-induced pro-inflammatory state significantly impacts COVID-19 outcomes in patients with cancer. The FLARE score, derived from circulating inflammatory markers, emerges as an easy-to-use, globally accessible, effective tool for clinicians to identify patients with cancer at heightened risk of severe COVID-19 complications and early mortality who might benefit most from immediate and intensive treatment strategies. Furthermore, our findings underscore the significance of immature neutrophils in the progression of COVID-19 in patients with cancer, advocating for further investigation into how these cells contribute to both cancer and COVID-19 disease., E.S. was supported by the Contracte Clínic Recerca “Emili Letang i Josep Font” 2022 and I Predoctoral Grant in Precision Oncology, 2022 (Cátedra UB IOP). L.M. received funding from the Beca SEOM retorno 2019; ESMO fellowship 2019–2021; Contrato Juan Rodes 2020 (ISCIII, Ministry of Health; JR20/00019); Ayuda Juan Rodés SEOM 2020; Ayuda de la Acción Estratégica en Salud—ISCIII FIS 2021 (PI21/01653); Beca SEOM para Proyectos de Investigación en Immunoncología 2021; Beca SEOM-ASTRAZENECA para Proyectos de Investigación para Grupo Emergente 2022; RADONORM, funded by the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 900009; Grupo Español de Tumores Huérfanos e infrecuentes (GETHI), Convocatoria Inés de Pablo Llorens 2023; and Becas Gilead a la Investigación Biomédica 2023. A.P. received funding from the Fundación CRIS contra el cáncer PR_EX_2021–14, Agència de Gestó d’Ajuts Universitaris i de Recerca 2021 SGR 01156, Fundación Fero BECA ONCOXXI21, Instituto de Salud Carlos III PI22/01017, Asociación Cáncer de Mama Metastásico IV Premios M. Chiara Giorgetti, Breast Cancer Research Foundation BCRF-23–198, and RESCUER, funded by the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 847912. Any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of funding entities. The preliminary results of this study were presented at ESMO Congress 2020 [38] and ASCO 2022 [39] as poster communications. During the preparation of this work, the author(s) used ChatGPT4 in the writing process. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy

  • Pascual, Tomás
  • Fernandez-Martinez, Aranzazu
  • Agrawal, Yash
  • Pfefferle, Adam
  • Chic, Nuria
  • Brasó Maristany, Fara
  • Gonzàlez-Farré, Blanca
  • Paré, Laia
  • Villacampa, Guillermo
  • Saura, Cristina
  • Hernando, Cristina
  • Muñoz, Montserrat
  • Galván, Patricia
  • Gonzàlez Farré, Xavier
  • Oliveira, Mafalda
  • Gil-Gil, Miguel
  • Ciruelos, Eva
  • Villagrasa, Patricia
  • Gavilá, Joaquín
  • Prat, Aleix
  • Perou, Charles
The study was conceived and designed by SOLTI investigators. Novartis funded the CORALLEEN study and provided ribociclib for the study. NanoString provided CE marked Prosigna tests for the study. This correlative analysis was supported by funds from the NCI Breast SPORE program (P50- CA058223), by the Breast Cancer Research Foundation, and by the Susan G. Komen (to C.M.P). The authors thank the LCCC Office of Genomics Research (OGR) for project management through the UNC core facilities, the LCCC Translational Genomics Lab (TGL) for RNAseq library preparation, and the High-Throughput Sequencing Facility (HTSF) for sequencing. The research was also funded by Breast Cancer Research Foundation-AACR Career Development Award: 19-20-26-PRAT (to A.P.), and Breast Cancer Now Catalyst Grant: 2018NovPCC1294 (to A.P.), RESCUER, funded by European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 847912 (to A.P.), Fundacio´ La Marato´ TV3: 201935-30 (to A.P.). Fundación CRIS contra el cáncer (PR_EX_2021-14) (to A.P.), Fundación científica AECC Ayudas Investigador AECC 2021 (INVES21943BRAS) (to F.B.M.), Fundación SEOM, Becas FSEOM para Formación en Investigación en Centros de Referencia en el Extranjero 2018 (to T.P.)., In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the CORALLEEN trial. 106 women with untreated PAM50-defined Luminal B early breast cancers were randomly assigned to receive neoadjuvant ribociclib and letrozole or standard-of-care chemotherapy. Ki67 immunohistochemistry, tumor-infiltrating lymphocytes quantification, and RNA sequencing were obtained from tissue biopsies pre-treatment, on day 14 of treatment, and tumor specimens from surgical resection. Results showed that at surgery, Ki67 and the PAM50 proliferation scores were lower after ribociclib compared to chemotherapy. However, consistent reactivation of tumor cell proliferation from day 14 to surgery was only observed in the ribociclib arm. In tumors with complete cell cycle arrest (CCCA) at surgery, PAM50 proliferation scores were lower in the ribociclib arm compared to chemotherapy (p < 0.001), whereas the opposite was observed with tumor cellularity (p = 0.002). Gene expression signatures (GES) associated with antigen-presenting cells (APCs) and innate immune system activity showed increased expression post-chemotherapy but decreased expression post-ribociclib. Interferon-associated GES had decreased expression with CCCA and increased expression with non-CCCA. Our findings suggest that while both treatment strategies decreased proliferation, the depth and the patterns over time differed by treatment arm. Immunologically, ribociclib was associated with downregulated GES associated with APCs and the innate immune system in Luminal B tumors, contrary to existing preclinical data. Further studies are needed to understand the effect of CDK4/6 inhibition on the tumor cells and microenvironment, an effect which may vary according to tumor subtypes., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

  • Martínez-Sáez, Olga
  • Chic Ruché, Núria
  • Pascual, Tomás
  • Adamo, Barbara
  • Vidal Losada, Maria
  • Gonzalez-Farre, Xavier
  • Sanfeliu Torres, Esther
  • Schettini, Francesco
  • Conte, Benedetta
  • Brasó-Maristany, Fara
  • Rodriguez, Adela
  • Martínez, Debora
  • Galván, Patricia
  • Rodríguez, Ana Belén
  • Martínez, Antonio
  • Muñoz Mateu, Montserrat
  • Prat Aparicio, Aleix
Purpose: The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects most PIK3CA mutations in BC. This information is critical as patients and clinicians are using this and other genomic assays to indicate alpelisib. Methods: Data from 6338 patients with BC was explored across 10 publicly available studies. The primary objective was to evaluate the proportion and distribution of PIK3CA mutations in BC. Secondary objectives were (1) to evaluate in silico the spectrum of PIK3CA mutations in BC that would be captured by the therascreen panel; (2) to evaluate the proportion and distribution of PIK3CA mutations in hormone receptor-positive/HER2-negative (HR+/HER2-), HER2+, and triple-negative BC (TNBC); and (3) to explore the identification of PIK3CA mutations in a cohort of 48 HR+/HER2- advanced BC patients by the Guardant B360 circulating tumor DNA (ctDNA) assay. Results: Patients with PIK3CAmut tumors represented 35.7% (2261/6338). Five PIK3CA mutations comprised 73% of all PIK3CA mutations: H1047R (35%), E545K (17%), E542K (11%), N345K (6%), and H1047L (4%). Therascreen gene list would capture 72% of all PIK3CA mutations and 80% of patients with a known PIK3CAmut BC. Among patients with double PIK3CAmut tumors (12% of all PIK3CAmut), the therascreen panel would capture 78% as harboring 1 single PIK3CA mutation, 17% as PIK3CAmut undetected, and 5% as PIK3CA double-mut. PIK3CA mutation rates were lower in TNBC (16%) compared to HR+/HER2 (42%) and HER2+ (31%) BC; however, the distribution of the 4 main PIK3CA mutations across subtypes was similar. Finally, 28% of PIK3CA mutations identified in ctDNA in 48 patients with advanced HR+/HER2- BC were not part of the therascreen panel. Conclusion: PIK3CA mutations in BC are heterogenous and ~ 20% of patients with a known PIK3CA mutation, and 95% with a known double PIK3CAmut tumor, would not be captured by the therascreen panel. Finally, the clinical utility of PIK3CA mutations not present in the therascreen companion diagnostic assay or identified by other sequencing-based assays needs further investigation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinical, pathological and PAM50 gene expression features of HER2-low breast cancer

  • Prat Aparicio, Aleix
  • Schettini, Francesco
  • Chic Ruché, Núria
  • Brasó-Maristany, Fara
  • Paré, Laia
  • Pascual, Tomás
  • Conte, Benedetta
  • Martínez-Sáez, Olga
  • Adamo, Barbara
  • Vidal Losada, Maria
  • Fernández Martínez, Aranzazu
  • González Farré, Blanca
  • Sanfeliu Torres, Esther
  • Cejalvo Andújar, Juan Miguel
  • Perrone, Giuseppe
  • Sabarese, Giovanna
  • Zalfa, Francesca
  • Villagrasa, Patricia
  • Gavilá, Joaquín
  • Barrios, Carlos H.
  • Lluch, Ana
  • Martín, Miguel
  • Placido, Sabino De
  • Barnadas, Esther
  • Locci, Mariavittoria
  • Peg, Vicente
  • Fasan, Roberta
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts

  • Òdena, Andreu
  • Casals, Eloi
  • Molina, Cristina
  • Coşkun, Meriç
  • Guzman Torres, Marta
  • Brasó Maristany, Fara
  • García-Galea, Eduardo
  • Herencia Ropero, Andrea
  • Domènech Garcia, Heura
  • Rodríguez, Olga
  • Grueso, Judit
  • Dienstmann, Rodrigo
  • Oliveira, Mafalda
  • Monserrat, Laia
  • Serra, Violeta
Patritumab deruxtecan; Xenografts; Breast cancer, Patritumab deruxtecan; Xenoinjertos; Cáncer de mama, Patritumab deruxtecan; Xenoempelt; Càncer de mama, Novel antibody-drug conjugates (ADCs) have shown potent antitumor activity across multiple cancer types. However, the key determinants of therapeutic response remain under investigation. In this study, we aimed to identify potential determinants of long-term response to patritumab deruxtecan (HER3-DXd; MK-1022), a HER3-directed ADC linked to a potent topoisomerase I inhibitor (TOP1i) payload, using a cohort of thirty-one breast cancer (BC) patient-derived xenograft (PDX) models. Fourteen out of 31 (45%) PDXs exhibited a profound and sustained response to HER3-DXd. Basal-like PAM50 intrinsic subtype, limited prior exposure to chemotherapy and intrinsic sensitivity to the TOP1i irinotecan were associated with long-term response. Additionally, HER3-DXd showed sustained activity in BRCA1/BRCA2-mutated PARPi-resistant PDX models. Long-term responders exhibited persistent DNA damage and lacked early transcriptional activation of the G2/M cell cycle checkpoint that allow for DNA repair and RNA-DNA hybrid (R-loop) resolution, in parallel resulting in immune pathways transcriptional activation. Notably, characteristics linked to long-term response were primarily associated with the TOP1i payload activity., VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA program from the Generalitat de Catalunya for their support on this research. This study was supported by the Asociación Española Cáncer de Mama Metastásico (AECMM) (III Metapremio M. Chiara Giorgetti 2021) and by the Catalan Agency AGAUR-FEDER (2021 SGR 01510 to V. Serra). V. Serra received funds from the Instituto de Salud Carlos III (ISCIII), and co-funded by the European Union (PI20/00892 and CPII19/00033). The FERO Foundation and GHD also provided support to V. Serra. A. Òdena and L. Monserrat received fellowships from the Agency for Management of University and Research Grants (2022 FI_B 00664 and AGAUR 2019 FI_B 01199, respectively). F. Brasó-Maristany received funding from Fundación científica AECC Ayudas Investigador AECC 2021 (INVES21943BRAS) and Fundación Contigo (HIMALAIA). A. Herencia-Ropero received funding from Generalitat de Catalunya (PERIS SLT017/20/000081). F. Pedretti received a fellowship from La Caixa Foundation (ID 100010434) (LCF/BQ/DI19/11730051). H. Domènech received a Severo Ochoa fellowship from the Spanish Ministry of Science and Innovation (PRE2021-099087). A. Esteve-Codina. reports that Institutional support to CNAG was provided by the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, and by the Generalitat de Catalunya through the Departament de Salut and the Departament de Recerca i Universitats. S. Chandarlapaty is supported by MSK Cancer Center Support Grant P30 CA008748 and the BCRF. A. Prat received funding from the Breast Cancer Research Foundation (BCRF-22-198, BCRF-23-198, BCRF-24-198), Beca Marta Santamaría, Fundación CRIS contra el Cancer (PR_EX_2021-14), Agència de Gestó d’Ajuts Universitaris I de Recerca (2021 SGR 01156), Fundación Fero (ONCOXXI21), Asociación Cáncer de Mama Metastásico (IV Premios M. Chiara Giorgetti), PI22/01017: funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and RESCUER: funded by European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 847912. We would like to acknowledge Daiichi Sankyo and Merck Inc. for providing the HER3-DXd and the IgG-DXd and Astrazeneca Inc. for supplying the olaparib used in the study. Finally, we would like to acknowledge the patients who donate samples for the generation of the PDX models used in this study.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Unexpected Durable Complete Response With Anti–PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis

  • Pesántez, David
  • Angelats, Laura
  • Sirico, Marianna
  • Victoria Ruiz, Iván
  • Indacochea Cusirramos, Alberto
  • Sanfeliu Torres, Esther
Soft-tissue sarcomes; Biomarker Analysis; Undifferentiated Pleomorphic Sarcoma, Sarcomas de tejidos blandos; Análisis de Biomarcadores; Sarcoma pleomórfico indiferenciado, Sarcomes de teixit tou; Anàlisi de biomarcadors; Sarcoma pleomòrfic indiferenciat, Soft-tissue sarcomas (STSs) are a heterogeneous group of tumors, representing approximately 1% of adult malignancies.1 Within STSs, undifferentiated pleomorphic sarcomas (UPSs) are one of the most frequent subgroups (5%-15%).2 Treatment options of advanced UPS remain limited, and the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12 months.3 UPS is characterized by a high level of genomic instability, as indicated by its complex karyotype with low tumor mutational burden (TMB) but high copy number alterations.4,5 This feature can be theoretically associated with higher immunogenicity because of a potential increase in neoantigen formation.6 For this reason, there is potential role for immunotherapy with immune checkpoint inhibitors (ICIs) in this subset of patients.7 Here, we report the case of a patient with metastatic UPS of the chest wall successfully treated with an anti–PD-L1 ICI at the Clinical Trial Unit of the Hospital Clinic of Barcelona (HCB), who experienced an exceptionally prolonged complete response (CR). Because of the lack of biomarkers for the correct identification of patients with UPS benefiting the most from ICIs, an extensive clinicopathological and molecular profiling was performed to explain this uncommon response, F.S. received a European Society for Medical Oncology (ESMO) Fellowship—Translational and the 2021 BBVA Foundation/Hospital Clinic of Barcelona Joan Rodes´ —Jose Baselga Advanced Research Contract in Oncology. F.S. is also recipient of a Rio Hortega 2022 Contract (Ministry of Health, Spain). L.A. is recipient of a Rio Hortega 2020 Contract (Ministry of Health, Spain). F.B.-M. received the Ayuda Investigador AECC 2021 (INVES21943BRAS) from Fundacion´ cient´ıfica AECC. A.P. has received funding from Fundacion CRIS ´ contra el cancer PR_EX_2021-14, Ag ´ encia de Gest ` o d ´ ’Ajuts Universitaris i de Recerca 2021 SGR 01156, Fundacion Fero BECA ´ ONCOXXI21, Instituto de Salud Carlos III PI22/01017, Asociacion´ Cancer de Mama Metast ´ asico IV Premios M. Chiara Giorgetti, Breast ´ Cancer Research Foundation BCRF-23-198, and RESCUER, funded by European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 847912.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

  • Schettini, Francesco
  • Chic, Nuria
  • Brasó-Maristany, Fara
  • Pascual, Tomás
  • Peg Camara, Vicente
  • Fasani, Roberta
  • Paré, Laia
  • Conte, Benedetta
Càncer de mama; Genòmica del càncer; Recerca translacional, Cáncer de mama; Genómica del cáncer; Investigación traslacional, Breast cancer; Cancer genomics; Translational research, Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression., This work was supported by the grants from the European Union’s Horizon 2020 Research and Innovation Programme under Grant agreement No. 847912 (to A.P.), the Instituto de Salud Carlos III-PI16/00904 (to A.P.), Pas a Pas (to A.P.), Save the Mama (to A.P.), Breast Cancer Now-2018NOVPCC1294 (to A.P.), Fundación Científica Asociación Española Contra el Cáncer-Ayuda Postdoctoral AECC 2017 (to F.B.-M.), Fundación SEOM, Becas FSEOM para Formación en Investigación en Centros de Referencia en el Extranjero 2018 (to T.P.) and PhD4MD - Departament de Salut expedient SLT008/18/00122 (to N.C.).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

ERBB2mRNA expression and response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-positive breast cancer

  • Griguolo, Gaia
  • Brasó-Maristany, Fara
  • González Farré, Blanca
  • Pascual, Tomás
  • Chic Ruché, Núria
  • Saurí, Tamara
  • Kates, Ronald
  • Gluz, Oleg
  • Martínez, Débora
  • Paré, Laia
  • Tsvetkova, Vassilena
  • Pesantez, David
  • Vidal Losada, Maria
  • Adamo, Barbara
  • Muñoz Mateu, Montserrat
  • Galván, Patricia
  • Barberá, Laura
  • Cuatrecasas Freixas, Miriam
  • Christgen, Mathias
  • Kreipe, Hans
  • Monge Escartín, Inés
  • Villagrasa, Patricia
  • Soy Muner, Dolors
  • Giarratano, Tommaso
  • Dieci, Maria Vittoria
  • Conte, Pierfranco
  • Harbeck, Nadia
  • Guarneri, Valentina
  • Prat Aparicio, Aleix
Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA.We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed para n-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally,
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

  • Prat, Aleix|||0000-0003-2377-540X
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Martínez-Sáez, Olga|||0000-0001-8686-0236
  • Sanfeliu, Esther|||0000-0002-7974-3346
  • Bellet Ezquerra, Meritxell|||0000-0001-8859-8307
  • Galván, Patricia
  • Martínez, Débora
  • Pascual, Tomás|||0000-0001-8431-3183
  • Marín Aguilera, Mercedes
  • Rodríguez, Anna
  • Chic, Nuria
  • Adamo, Barbara
  • Paré Brunet, Laia
  • Vidal Losada, Maria|||0000-0003-1992-5727
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
  • Gómez-Rey, Marina|||0000-0002-9636-3281
  • Oliveira, Mafalda|||0000-0001-9152-8799
  • Felip, Eudald|||0000-0002-3812-1313
  • Matito, Judit|||0000-0001-7560-7737
  • Sánchez-Bayona, Rodrigo
  • Suñol Camas, Anna
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Ciruelos, Eva|||0000-0002-2796-1042
  • Tolosa, Pablo|||0000-0002-3747-4766
  • Muñoz, Montserrat
  • González Farré, Blanca|||0000-0002-1796-7248
  • Villagrasa, Patricia
  • Parker, Joel S.
  • Perou, Charles M.|||0000-0001-9827-2247
  • Vivancos, Ana|||0000-0003-2888-6512
Liquid biopsy has proven valuable in identifying individual genetic alterations; however, the ability of plasma ctDNA to capture complex tumor phenotypes with clinical value is unknown. To address this question, we have performed 0.5X shallow whole-genome sequencing in plasma from 459 patients with metastatic breast cancer, including 245 patients treated with endocrine therapy and a CDK4/6 inhibitor (ET + CDK4/6i) from 2 independent cohorts. We demonstrate that machine learning multi-gene signatures, obtained from ctDNA, identify complex biological features, including measures of tumor proliferation and estrogen receptor signaling, similar to what is accomplished using direct tumor tissue DNA or RNA profiling. More importantly, 4 DNA-based subtypes, and a ctDNA-based genomic signature tracking retinoblastoma loss-of-heterozygosity, are significantly associated with poor response and survival outcome following ET + CDK4/6i, independently of plasma tumor fraction. Our approach opens opportunities for the discovery of additional multi-feature genomic predictors coming from ctDNA in breast cancer and other cancer-types. Plasma ctDNA is a promising method to determine patient outcome in multiple cancer types. Here, the authors use shallow WGS to create machine learning signatures to identify tumor phenotypes and predict therapy response in patients with metastatic breast cancer.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

  • Schettini, Francesco
  • Chic, Nuria
  • Brasó-Maristany, Fara
  • Pascual, Tomás
  • Peg Camara, Vicente
  • Fasani, Roberta
  • Paré, Laia
  • Conte, Benedetta
Càncer de mama; Genòmica del càncer; Recerca translacional, Cáncer de mama; Genómica del cáncer; Investigación traslacional, Breast cancer; Cancer genomics; Translational research, Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression., This work was supported by the grants from the European Union’s Horizon 2020 Research and Innovation Programme under Grant agreement No. 847912 (to A.P.), the Instituto de Salud Carlos III-PI16/00904 (to A.P.), Pas a Pas (to A.P.), Save the Mama (to A.P.), Breast Cancer Now-2018NOVPCC1294 (to A.P.), Fundación Científica Asociación Española Contra el Cáncer-Ayuda Postdoctoral AECC 2017 (to F.B.-M.), Fundación SEOM, Becas FSEOM para Formación en Investigación en Centros de Referencia en el Extranjero 2018 (to T.P.) and PhD4MD - Departament de Salut expedient SLT008/18/00122 (to N.C.).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts

  • Òdena, Andreu
  • Casals, Eloi
  • Molina, Cristina
  • Coşkun, Meriç
  • Guzman Torres, Marta
  • Brasó Maristany, Fara
  • García-Galea, Eduardo
  • Herencia Ropero, Andrea
  • Domènech Garcia, Heura
  • Rodríguez, Olga
  • Grueso, Judit
  • Dienstmann, Rodrigo
  • Oliveira, Mafalda
  • Monserrat, Laia
  • Serra, Violeta
Patritumab deruxtecan; Xenografts; Breast cancer, Patritumab deruxtecan; Xenoinjertos; Cáncer de mama, Patritumab deruxtecan; Xenoempelt; Càncer de mama, Novel antibody-drug conjugates (ADCs) have shown potent antitumor activity across multiple cancer types. However, the key determinants of therapeutic response remain under investigation. In this study, we aimed to identify potential determinants of long-term response to patritumab deruxtecan (HER3-DXd; MK-1022), a HER3-directed ADC linked to a potent topoisomerase I inhibitor (TOP1i) payload, using a cohort of thirty-one breast cancer (BC) patient-derived xenograft (PDX) models. Fourteen out of 31 (45%) PDXs exhibited a profound and sustained response to HER3-DXd. Basal-like PAM50 intrinsic subtype, limited prior exposure to chemotherapy and intrinsic sensitivity to the TOP1i irinotecan were associated with long-term response. Additionally, HER3-DXd showed sustained activity in BRCA1/BRCA2-mutated PARPi-resistant PDX models. Long-term responders exhibited persistent DNA damage and lacked early transcriptional activation of the G2/M cell cycle checkpoint that allow for DNA repair and RNA-DNA hybrid (R-loop) resolution, in parallel resulting in immune pathways transcriptional activation. Notably, characteristics linked to long-term response were primarily associated with the TOP1i payload activity., VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA program from the Generalitat de Catalunya for their support on this research. This study was supported by the Asociación Española Cáncer de Mama Metastásico (AECMM) (III Metapremio M. Chiara Giorgetti 2021) and by the Catalan Agency AGAUR-FEDER (2021 SGR 01510 to V. Serra). V. Serra received funds from the Instituto de Salud Carlos III (ISCIII), and co-funded by the European Union (PI20/00892 and CPII19/00033). The FERO Foundation and GHD also provided support to V. Serra. A. Òdena and L. Monserrat received fellowships from the Agency for Management of University and Research Grants (2022 FI_B 00664 and AGAUR 2019 FI_B 01199, respectively). F. Brasó-Maristany received funding from Fundación científica AECC Ayudas Investigador AECC 2021 (INVES21943BRAS) and Fundación Contigo (HIMALAIA). A. Herencia-Ropero received funding from Generalitat de Catalunya (PERIS SLT017/20/000081). F. Pedretti received a fellowship from La Caixa Foundation (ID 100010434) (LCF/BQ/DI19/11730051). H. Domènech received a Severo Ochoa fellowship from the Spanish Ministry of Science and Innovation (PRE2021-099087). A. Esteve-Codina. reports that Institutional support to CNAG was provided by the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, and by the Generalitat de Catalunya through the Departament de Salut and the Departament de Recerca i Universitats. S. Chandarlapaty is supported by MSK Cancer Center Support Grant P30 CA008748 and the BCRF. A. Prat received funding from the Breast Cancer Research Foundation (BCRF-22-198, BCRF-23-198, BCRF-24-198), Beca Marta Santamaría, Fundación CRIS contra el Cancer (PR_EX_2021-14), Agència de Gestó d’Ajuts Universitaris I de Recerca (2021 SGR 01156), Fundación Fero (ONCOXXI21), Asociación Cáncer de Mama Metastásico (IV Premios M. Chiara Giorgetti), PI22/01017: funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and RESCUER: funded by European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 847912. We would like to acknowledge Daiichi Sankyo and Merck Inc. for providing the HER3-DXd and the IgG-DXd and Astrazeneca Inc. for supplying the olaparib used in the study. Finally, we would like to acknowledge the patients who donate samples for the generation of the PDX models used in this study.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Unexpected Durable Complete Response With Anti–PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis

  • Pesántez, David
  • Angelats, Laura
  • Sirico, Marianna
  • Victoria Ruiz, Iván
  • Indacochea Cusirramos, Alberto
  • Sanfeliu Torres, Esther
Soft-tissue sarcomes; Biomarker Analysis; Undifferentiated Pleomorphic Sarcoma, Sarcomas de tejidos blandos; Análisis de Biomarcadores; Sarcoma pleomórfico indiferenciado, Sarcomes de teixit tou; Anàlisi de biomarcadors; Sarcoma pleomòrfic indiferenciat, Soft-tissue sarcomas (STSs) are a heterogeneous group of tumors, representing approximately 1% of adult malignancies.1 Within STSs, undifferentiated pleomorphic sarcomas (UPSs) are one of the most frequent subgroups (5%-15%).2 Treatment options of advanced UPS remain limited, and the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12 months.3 UPS is characterized by a high level of genomic instability, as indicated by its complex karyotype with low tumor mutational burden (TMB) but high copy number alterations.4,5 This feature can be theoretically associated with higher immunogenicity because of a potential increase in neoantigen formation.6 For this reason, there is potential role for immunotherapy with immune checkpoint inhibitors (ICIs) in this subset of patients.7 Here, we report the case of a patient with metastatic UPS of the chest wall successfully treated with an anti–PD-L1 ICI at the Clinical Trial Unit of the Hospital Clinic of Barcelona (HCB), who experienced an exceptionally prolonged complete response (CR). Because of the lack of biomarkers for the correct identification of patients with UPS benefiting the most from ICIs, an extensive clinicopathological and molecular profiling was performed to explain this uncommon response, F.S. received a European Society for Medical Oncology (ESMO) Fellowship—Translational and the 2021 BBVA Foundation/Hospital Clinic of Barcelona Joan Rodes´ —Jose Baselga Advanced Research Contract in Oncology. F.S. is also recipient of a Rio Hortega 2022 Contract (Ministry of Health, Spain). L.A. is recipient of a Rio Hortega 2020 Contract (Ministry of Health, Spain). F.B.-M. received the Ayuda Investigador AECC 2021 (INVES21943BRAS) from Fundacion´ cient´ıfica AECC. A.P. has received funding from Fundacion CRIS ´ contra el cancer PR_EX_2021-14, Ag ´ encia de Gest ` o d ´ ’Ajuts Universitaris i de Recerca 2021 SGR 01156, Fundacion Fero BECA ´ ONCOXXI21, Instituto de Salud Carlos III PI22/01017, Asociacion´ Cancer de Mama Metast ´ asico IV Premios M. Chiara Giorgetti, Breast ´ Cancer Research Foundation BCRF-23-198, and RESCUER, funded by European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 847912.